{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:44:35Z","timestamp":1787330675843,"version":"build-2736575974"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In Thai patients with non-valvular atrial fibrillation (NVAF), anticoagulation quality with warfarin remains suboptimal. Existing prediction tools for poor international normalized ratio (INR) control, such as the SAMe-TT\n                      <jats:sub>2<\/jats:sub>\n                      R\n                      <jats:sub>2<\/jats:sub>\n                      score, perform poorly in this population. Identifying population-specific determinants of time in therapeutic range (TTR) may improve risk stratification and inform clinical decision-making.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center, retrospective cohort study of adult patients with NVAF taking warfarin between 2016 and 2019. TTR was calculated using the Rosendaal method, with a target INR range of 2.0\u20133.0. Logistic regression analysis was performed to identify independent predictors of suboptimal anticoagulation control (TTR &lt;65%). A novel risk score was derived from the regression coefficients and evaluated using receiver operating characteristic (ROC) curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1,322 patients (median age 68 years; 57% female), median TTR was 50.5% (IQR 29.8\u201369.0), and 70% had TTR &lt;65%. Independent predictors of suboptimal TTR included age \u226565 years, heart failure, hypertension, and drug\u2013drug interactions with warfarin, while prior warfarin use \u22651 year was protective (all P&lt;0.05). These variables were incorporated into the AHfHDP score (range, \u22122 to 4). The AHfHDP score showed modest discrimination (C-statistic 0.64; 95% CI 0.61\u20130.67), outperforming SAMe-TT\n                      <jats:sub>2<\/jats:sub>\n                      R\n                      <jats:sub>2<\/jats:sub>\n                      (C-statistic, 0.53).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Warfarin anticoagulation control in Thai patients with NVAF remains suboptimal. The AHfHDP score demonstrated modest predictive performance and superior discrimination compared to the SAMe-TT\n                      <jats:sub>2<\/jats:sub>\n                      R\n                      <jats:sub>2<\/jats:sub>\n                      score. However, its overall predictive ability remained limited, and external validation is required before clinical application.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296261480894","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:03:24Z","timestamp":1787137404000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors Associated With Time in Therapeutic Range Among Thai Patients with Non-valvular Atrial Fibrillation Taking Warfarin: Development of AHfHDP Score"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2219-7565","authenticated-orcid":false,"given":"Pitchapong","family":"Kositchaiwat","sequence":"first","affiliation":[{"name":"Chulalongkorn University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubonwan","family":"Sapoo","sequence":"additional","affiliation":[{"name":"Maharat Nakhon Ratchasima Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutthada","family":"Areepium","sequence":"additional","affiliation":[{"name":"Chulalongkorn University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-0897","authenticated-orcid":false,"given":"Krittin","family":"Bunditanukul","sequence":"additional","affiliation":[{"name":"Chulalongkorn University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62343-0"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.011"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1160\/th13-06-0443"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.0199"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2019143"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0054"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651587"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2292"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10944"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1160\/th13-11-0948"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164076"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2013.03.017"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42444-021-00038-8"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01466-0"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.042"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.11.026"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261480894","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296261480894","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261480894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:19:41Z","timestamp":1787329181000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296261480894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":18,"alternative-id":["10.1177\/10760296261480894"],"URL":"https:\/\/doi.org\/10.1177\/10760296261480894","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"10760296261480894"}}